US Edition
Redefining the future of regenerative medicine
Summary by themarketonline.ca
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
All
Left
Center
Right
A 45-year-old man successfully receives the first human bladder transplant, opening new expectations in regenerative medicine.Read more The first human bladder transplant in UCLA marks a milestone in medicine in News.es.
Redefining the future of regenerative medicine
NurExone Biologic Inc. is a TSX Venture Exchange (TSXV:NRX), (OTCQB:NRXBF), and Frankfurt-listed biotech company focused on developing regenerative exosome-based therapies for central nervous system injuries. Its lead product, ExoPTEN, has demonstrated strong preclinical data supporting clinical potential in treating acute spinal cord and optic nerve injury, both multi-billion-dollar markets. Regulatory milestones, including obtaining the Orphan…
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
